We are committed to patients with hemophilia and the bleeding disorders community.

Ongoing focus

icon: ongoing focus

At Novo Nordisk, we believe that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.

Product portfolio

icon: product portfolio

We aspire to be a respected leader in the health care industry, helping patients with treatments for:

• FVII deficiency
• FVIII deficiency
• FVIII deficiency with inhibitors
• FIX deficiency with inhibitors
• FXIII deficiency
• Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
• Acquired hemophilia

Environmental awareness

icon: environmental awareness

We also strive to minimize the environmental impact of our activities. Our facilities in Denmark supply quality products in a socially responsible and environmentally sound way, using 100% renewable energy.

The Triple Bottom Line.

The Triple Bottom Line (TBL) is Novo Nordisk’s way of doing business. We believe that a healthy economy, environment, and society are fundamental to long-term business success. We are one of only four companies in the world who have incorporated our philosophy into our company bylaws.

Everything we do and every decision we make is informed by the three pillars of TBL:

Social impact.

Social responsibility is about caring for people. This applies to the people who depend on our products, as well as to our employees. We work to continuously integrate social, health, and safety considerations into our daily business.


Environmental responsibility.

Environmental soundness addresses our impact on the external environment – and we've taken a concerted approach to ensure that our efforts to be green pay off.

The campus of our LEED Silver certified U.S. Headquarters demonstrates our approach to being responsible stewards of our environment, driven by the company’s commitment to help people live healthy lives, and consistent with Novo Nordisk's TBL business model.

Our campus utilized recycled and locally-sourced materials, and is fully powered by renewable energy from wind, solar, and hydro sources—a feature that is expected to lead to a 30 percent reduction in energy costs.


Financial performance.

Economic viability is about managing the business in a way that secures growth and value creation, and delivers competitive performance in these areas. Investing in our employees contributes to our award-winning workplace and supports our goal of delivering innovative achievements.

Novo Nordisk Inc. has been ranked in Fortune Magazine's Best Places to Work listing every year since 2009. Most recently, Novo Nordisk was presented with the New Good Neighbor Award by the New Jersey Business & Industry Association. This award was based on a variety of factors, including economic benefit/job creation, architectural merit, and community involvement.

Novo Nordisk is also committed to investing in Research and Development. In 2016, 13% of sales went towards funding R&D projects across the organization

Selected Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

  • NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.
  • Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.
  • People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

  • The most common and serious side effects are blood clots.
  • Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

  • Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).

Please click here for Prescribing Information.

NovoSeven® RT is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.